HKD39.10
3.49% today
Hong Kong, Sep 22, 07:15 am CET
ISIN
KYG970081173
Symbol
2269
Index

WuXi Biologics Stock price

HKD37.78
+8.00 26.86% 1M
+9.28 32.56% 6M
+20.22 115.15% YTD
+25.66 211.72% 1Y
-11.47 23.29% 3Y
-25.15 39.97% 5Y
+28.36 301.20% 10Y
+28.36 301.20% 20Y
Hong Kong, Closing price Fri, Sep 19 2025
-1.12 2.88%

Key metrics

Basic
Market capitalization
HKD159.0b
Enterprise Value
HKD150.9b
Net debt
positive
Cash
HKD13.7b
Shares outstanding
4.1b
Valuation (TTM | estimate)
P/E
35.0 | 30.5
P/S
7.3 | 6.6
EV/Sales
6.9 | 6.3
EV/FCF
-
P/B
3.2
Financial Health
Equity Ratio
73.4%
Return on Equity
8.0%
ROCE
12.2%
ROIC
11.9%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
HKD21.9b | HKD23.9b
EBITDA
- | HKD8.3b
EBIT
HKD6.9b | HKD6.8b
Net Income
HKD4.6b | HKD5.0b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
17.2% | 17.2%
EBITDA
- | 21.6%
EBIT
64.1% | 28.8%
Net Income
59.4% | 37.5%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
42.7%
EBITDA
- | 34.8%
EBIT
31.6%
Net
20.9% | 21.1%
Free Cash Flow
-
More
EPS
HKD1.1
FCF per Share
-
Short interest
-
Employees
13k
Rev per Employee
HKD1.6m
Show more

Is WuXi Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

WuXi Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a WuXi Biologics forecast:

26x Buy
81%
6x Hold
19%

Analyst Opinions

32 Analysts have issued a WuXi Biologics forecast:

Buy
81%
Hold
19%

Financial data from WuXi Biologics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
21,915 21,915
17% 17%
100%
- Direct Costs 12,568 12,568
10% 10%
57%
9,347 9,347
29% 29%
43%
- Selling and Administrative Expenses 2,511 2,511
3% 3%
11%
- Research and Development Expense 837 837
3% 3%
4%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6,914 6,914
64% 64%
32%
Net Profit 4,586 4,586
59% 59%
21%

In millions HKD.

Don't miss a Thing! We will send you all news about WuXi Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.

Head office Cayman Islands
CEO Zhi Chen
Employees 12,575
Founded 2010
Website www.wuxibiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today